In a meeting on 11th March 2005, the Board of Directors ruled on COLETICA’s consolidated accounts for the 2004 financial 2022.
Consolidated income statement (not yet audited)
In million € 2004 2003
Turnover 25.97 19.39
Operating income 4.99 1.17
Earnings before tax and extraordinary 5.20 1.15
Net profit 3.69 0.21
Turnover at a constant dollar rate is due to have reached €26.3 million, with the main geographical zones (US and Europe) contributing to this sustained activity level.
The margin on cost of sales rose from 63.4% to 65.6%.
Net earning power cleared the 13.5% mark as expected, taking it to 14.2%.
The balance sheet structure remains very healthy as at 31st December 2004; with equity of €17.06 million, cash of €10.07 million and financial liabilities amounting to €0.11 million.
The Board of Directors decided to propose at the next General Meeting the distribution of a €0.3 dividend, corresponding to the total of the provisional dividend paid in September 2004.
Exclusivity for talks and negotiations awarded to Engelhard Corporation
The shareholders are reminded that the family groups Lacoste, Cohen, Aubry, the Bioetica company and Mr. Pierre Devictor (majority group), as well as FCPI Axa Placement Innovation and Banque de Vizille awarded the Engelhard Corporation exclusivity for talks and negotiations on 11th February 2005, which will last until 31st March 2005. The Engelhard Corporation offer thus bears on a stake representing 77.87% of COLETICA’s registered capital for a price equal to €37.10 per share.
This offer was the subject of a press release which was published in La Tribune on 2nd March 2005 and can be consulted on the AMF website and the company website (www.coletica.fr).
Presentation of 2004 results
The 2004 results and COLETICA news will be announced in a debriefing which will be held on 24th March 2005 at 11.30am in Hôtel Meurice, 228 rue de Rivoli, 75001 Paris.
COLETICA is a major global player in active ingredients and related technologies for use in cosmetics and, more especially, skin-care products.
Focused on innovations and specific products and positioned upstream from the design of finished products for the cosmetics sector, present on 3 continents through its regional offices in Paris, New York and Tokyo, COLETICA provides the R&D departments of major cosmetics groups with the benefit of its expertise. Clients include Avon, Chanel, Clarins, Estée Lauder, Henkel, L’Oréal, LVMH, Natura, Pacific,…
With 56 families of international patent, COLETICA’s international development is being driven by its unique strengths.
ISIN Code: FR0004250165 – Reuters: CTIP.PA – Bloomberg: COLE FP
32, rue Saint-Jean de Dieu
Tel: 33 (4) 72 76 60 00
Fax: 33 (4) 72 76 70 24
Chief Financial Officer
e-mail: [email protected] ACTUS
Les Bureaux de Chalin
20, chemin Louis Chirpaz 69130 Ecully
Tel: 33 (4) 72 18 04 93 Fax: 33 (4) 72 18 04 99
e-mail: [email protected]